<DOC>
	<DOCNO>NCT00729287</DOCNO>
	<brief_summary>RATIONALE : Chemoprevention use certain drug keep cancer forming , grow , come back . The use selenium may keep bladder cancer grow come back . It yet know whether selenium effective placebo prevent cancer recurrence patient bladder cancer . PURPOSE : This randomized phase III trial study selenium see well work compare placebo prevent cancer recurrence patient bladder cancer .</brief_summary>
	<brief_title>Selenium Preventing Cancer Recurrence Patients With Bladder Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine effect selenium , administer standard care , prevent recurrence bladder cancer patient non-muscle-invasive transitional cell carcinoma bladder risk recurrence . Secondary - To determine effect selenium recurrence bladder cancer , term histological type , number , size . OUTLINE : Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral placebo daily addition standard care . - Arm II : Patients receive oral selenium daily addition standard care .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Selenium</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histopathologically confirm nonmuscleinvasive transitional cell carcinoma ( TCC ) bladder ( &lt; pT2 ) PATIENT CHARACTERISTICS : Able swallow pill Not pregnant Fertile patient must use effective contraception No malignancy within past 5 year No know hypersensitivity adverse reaction selenium No serious medical psychiatric illness would preclude give informed consent No condition , opinion investigator , may interfere safety patient evaluation study objective PRIOR CONCURRENT THERAPY : See Disease Characteristics More 30 day since prior daily dietary supplement contain selenium No concurrent selenium ( contain individual supplement , antioxidant mix , multivitamin ) intake No concurrent participation another study involve medical , surgical , nutritional , lifestyle intervention Concurrent participation followup phase another study allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>stage 0 bladder cancer</keyword>
	<keyword>stage I bladder cancer</keyword>
	<keyword>transitional cell carcinoma bladder</keyword>
</DOC>